Harel Insurance Investments & Financial Services Ltd. filed an amended Schedule 13G with the SEC on November 2, 2026, disclosing beneficial ownership of 70,418,201 ordinary shares of Teva Pharmaceutical Industries Ltd., representing 6.0% of the company's outstanding shares as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: Harel Insurance reported aggregate beneficial ownership of 70,418,201 ordinary shares of Teva Pharmaceutical, par value NIS 0.10 per share.
  • Percent of class: The 70,418,201 shares represent 6.0% of 1,165,296,084 ordinary shares issued and outstanding as of June 30, 2026.
  • Shared voting power: Harel Insurance reported shared voting power over 69,390,266 shares, with sole voting power of zero.
  • Shared dispositive power: Harel Insurance reported shared dispositive power over 70,418,201 shares, with sole dispositive power of zero.
  • Directly held shares: Only 1,015,197 ordinary shares are beneficially held for Harel Insurance's own account, with the filing stating it shall not be construed as an admission of beneficial ownership of more than that amount.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026, according to the cover page.

Harel Insurance Discloses Large Holding in Teva Through Managed Funds and Subsidiaries

According to the filing, Harel Insurance Investments & Financial Services Ltd., an Israeli company headquartered at 3 Aba Hillel Street, Ramat Gan 52118, Israel, submitted Amendment No. 2 to its Schedule 13G covering ordinary shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), a global pharmaceutical company headquartered at 124 Dvora Hanevi'a Street, Tel Aviv, Israel. The filing was signed by Alon Kaufman, Vice President, on November 2, 2026.

The filing describes how the reported 70,418,201 ordinary shares are held across several categories. According to Item 4, 68,375,069 shares are held for members of the public through provident funds, mutual funds, pension funds, insurance policies, and exchange traded funds managed by subsidiaries of the reporting person, with each subsidiary operating under independent management and making independent voting and investment decisions. An additional 1,027,935 shares are held in third-party client accounts managed by a subsidiary acting as portfolio manager, which has no voting power over those securities. The remaining 1,015,197 shares are held directly for Harel Insurance's own account.

The filing notes that the share count and percentage are based on 1,165,296,084 ordinary shares issued and outstanding as of June 30, 2026, as reported by Teva in its Annual Report on Form 10-Q filed with the SEC on July 29, 2026. Harel Insurance certified that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," quoting the standard Schedule 13G certification language.

What Was Disclosed

Harel Insurance Investments & Financial Services Ltd. filed an amended Schedule 13G disclosing 70,418,201 ordinary shares of Teva Pharmaceutical Industries Ltd., equal to 6.0% of the class, with the holding spread primarily across subsidiary-managed public funds and client accounts, and only 1,015,197 shares held for its own account.